ArticleNature communications2021
Antibody-based CCR5 blockade protects Macaques from mucosal SHIV transmission.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 19 citations in OpenAlex.
- Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species.PLoS pathogens · 2022Trial
- CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab.Frontiers in immunology · 2021Trial
- An ER stress-responsive RNA rheostat for programmable gene and mRNA therapies.Cell chemical biology · 2026Article
- Combination therapy with broadly neutralizing antibodies, antiretroviral therapy and CCR5 blockade limits viral reservoir seeding in infant macaque model of HIV.Nature microbiology · 2026Article
- Host-directed approaches in the pursuit of a cure for HIV.Antiviral research · 2025Review
- Effect of metabolic status on response to SIV infection and antiretroviral therapy in nonhuman primates.JCI insight · 2024Article
- Immune restoration by TIGIT blockade is insufficient to control chronic SIV infection.Journal of virology · 2024Article
- Allogeneic immunity clears latent virus following allogeneic stem cell transplantation in SIV-infected ART-suppressed macaques.Immunity · 2023Article
- Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies.Nature microbiology · 2023Article
- Adeno-associated virus-vectored delivery of HIV biologics: the promise of a "single-shot" functional cure for HIV infection.Journal of virus eradication · 2023Article
- TGFβ1Nature communications · 2023Article
- Editorial: Preclinical macaque models of viral diseases.Frontiers in immunology · 2023Article
- Cytomegalovirus-vaccine-induced unconventional T cell priming and control of SIV replication is conserved between primate species.Cell host & microbe · 2022Article
- Walk on the wild side: SIV infection in African non-human primate hosts-from the field to the laboratory.Frontiers in immunology · 2022Review
- Filling the Gaps in Antagonist CCR5 Binding, a Retrospective and Perspective Analysis.Frontiers in immunology · 2022Article
- Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy.Frontiers in immunology · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 7 institutions in 2 countries.
Xiao L Chang *Vaccine & Gene Therapy Institute, Portland, OR, USA.
Gabriela M Webb *Vaccine & Gene Therapy Institute, Portland, OR, USA.
Helen L WuVaccine & Gene Therapy Institute, Portland, OR, USA.ORCID 0000-0001-7101-5160
Justin M GreeneVaccine & Gene Therapy Institute, Portland, OR, USA.
Shaheed AbdulhaqqVaccine & Gene Therapy Institute, Portland, OR, USA.
Katherine B BatemanVaccine & Gene Therapy Institute, Portland, OR, USA.
Jason S ReedVaccine & Gene Therapy Institute, Portland, OR, USA.
Cleiton PessoaVaccine & Gene Therapy Institute, Portland, OR, USA.
Whitney C WeberVaccine & Gene Therapy Institute, Portland, OR, USA.ORCID 0000-0002-5868-8085
Nicholas MaierVaccine & Gene Therapy Institute, Portland, OR, USA.
Glen M ChewUniversity of Hawaii, Honolulu, HI, USA.
Roxanne M GilbrideVaccine & Gene Therapy Institute, Portland, OR, USA.
Lina GaoOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
Rebecca AgnorOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
Travis GiobbiOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
Jeffrey TorgersonOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
Don SiessOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
Nicole BurnettOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
Miranda FischerOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
Oriene ShielOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
Cassandra MoatsOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
Bruce PattersonIncellDX, Menlo Park, CA, USA.
Kush DhodyAmarex Clinical Research LLC, Germantown, MD, USA.
Scott KellyCytoDyn Inc., Vancouver, WA, USA.
Nader PourhassanCytoDyn Inc., Vancouver, WA, USA.
Diogo M MagnaniMassBiologics of the University of Massachusetts Medical School, Boston, MA, USA.ORCID 0000-0002-1773-2406
Jeremy SmedleyOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.ORCID 0000-0003-3369-4662
Benjamin N BimberVaccine & Gene Therapy Institute, Portland, OR, USA.
Nancy L HaigwoodVaccine & Gene Therapy Institute, Portland, OR, USA.
Scott G HansenVaccine & Gene Therapy Institute, Portland, OR, USA.
Timothy R BrownPalm Springs, Palm Springs, CA, USA.
Lishomwa C NdhlovuDepartment of Medicine, Division of Infectious Disease, Weill Cornell Medicine, New York, NY, USA. lndhlovu@med.cornell.edu.ORCID 0000-0001-5427-4187
Jonah B SachaVaccine & Gene Therapy Institute, Portland, OR, USA. Sacha@ohsu.edu.ORCID 0000-0002-7633-3122
Oregon National Primate Research Center · USVaccine and Gene Therapy InstituteCornell University · USDesert AIDS Project · USIncell Corporation (United States) · USUniversity of Hawaiʻi at Mānoa · USUniversity of Massachusetts Chan Medical School · US
Funding
Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9MNonhuman Primate Reagent ResourceU24AI126683 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Diogo Magnani · 2016 to 2026
$20.1MA nonhuman primate model of stem cell transplantation to understand determinants of post-transplant SIV clearanceR01AI129703 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI SACHA, JONAH B. · 2017 to 2025
$7.8MA Solid-Phase, Long-Acting CCR5 Monoclonal Antibody for HIV TransmissionR01AI154559 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI SACHA, JONAH B. · 2020 to 2024
$4.8MREGULATION OF HTLV I LTR IN IMMUNE AND NERVOUS SYSTEMSR01CA054559 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI JAIN, POOJA · 1991 to 2016
$4.8MNon-canonical epitope presentation and antigen processing by MHC-ER01AI175459 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Klaus J Fruh, Jonah B. Sacha · 2023 to 2026
$2.8MEmerging Roles of Higher-order Polyamines During TauopathiesR01AG054559 · NIA · UNIVERSITY OF SOUTH FLORIDA · PI LEE, DANIEL CARL · 2017 to 2021
$2.4MAntibody-Based Enhancement of CMV Vaccine Vectors for HIVK01OD026561 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI GREENE, JUSTIN · 2018 to 2020
$1.1MA CCR5 Blocking Antibody as HIV Pre-exposure ProphylaxisR21AI147723 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI SACHA, JONAH B. · 2019 to 2020
$459kNCI NIH HHS R01 CA054559NIAID NIH HHS R01 AI129703NIAID NIH HHS R01 AI154559NIAID NIH HHS R01 AI175459NIAID NIH HHS R21 AI147723NIAID NIH HHS U24 AI126683NIA NIH HHS R01 AG054559NIH HHS K01 OD026561NIH HHS P51 OD011092
Abstract
In the absence of a prophylactic vaccine, the use of antiretroviral therapy (ART) as pre-exposure prophylaxis (PrEP) to prevent HIV acquisition by uninfected individuals is a promising approach to slowing the epidemic, but its efficacy is hampered by incomplete patient adherence and ART-resistant variants. Here, we report that competitive inhibition of HIV Env-CCR5 binding via the CCR5-specific antibody Leronlimab protects rhesus macaques against infection following repeated intrarectal challenges of CCR5-tropic SHIV
Indexed as
AnimalsAntibodies, Monoclonal, HumanizedCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleHIV AntibodiesHIV InfectionsHumansMacaca mulattaMaleMucous MembranePre-Exposure ProphylaxisReceptors, CCR5Simian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusViral LoadAntibodies, Monoclonal, HumanizedCCR5 protein, humanHIV AntibodiesleronlimabReceptors, CCR5
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.